Balak Das Kurmi

Dr. Balak Das Kurmi

orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 January 2020 in Expert Opinion on Therapeutic Patents
Verified
Journal Article
Closed access
RPRishi Paliwal
Rishi Paliwal
SPShivani Rai Paliwal
Shivani Rai Paliwal
RKRameshroo Kenwat
Rameshroo Kenwat
BKBalak Das Kurmi
Balak Das Kurmi
MSMukesh Kumar Sahu
Mukesh Kumar Sahu
Introduction: Solid lipid nanoparticles (SLNs) are solid core lipid nanocarriers, which can hold both hydrophilic and hydrophobic drugs. They can be made up of biocompatible ingredients and therefore are one of the preferred choices for drug delivery. Surface modifications of SLNs may further provide unique features to them like mucoadhesiveness or targeting capability.Areas covered: In this review, the authors have covered areas from the basic introduction of SLNs to its applications in controlled drug delivery. More specifically, the authors have covered patents disclosed related to the SLNs for the period 2014-2019; however, a summary of patents of 2008-2013 is also included.Expert opinion: SLNs have been explored for development of compositions/formulations with improved therapeutics or cosmetic applications or for nutraceutical applications. Targeted SLNs compositions have been patented as evidenced from the literature; however, not such types of enough SLNs formulations have been claimed for the same.

27 April 2023 in Life
Verified
Journal Article
Open access
PDF file
LKLakshmi Kumari
Lakshmi Kumari
YCYash Choudhari
Yash Choudhari
PPPreeti Patel
Preeti Patel
GGGhanshyam Das Gupta
Ghanshyam Das Gupta
DCDilpreet singh chahal
Dilpreet singh chahal
BKBalak Das Kurmi
Balak Das Kurmi
A drug’s aqueous solubility is defined as the ability to dissolve in a particular solvent, and it is currently a major hurdle in bringing new drug molecules to the market. According to some estimates, up to 40% of commercialized products and 70–90% of drug candidates in the development stage are poorly soluble, which results in low bioavailability, diminished therapeutic effects, and dosage escalation. Because of this, solubility must be taken into consideration when developing and fabricating pharmaceutical products. To date, a number of approaches have been investigated to address the problem of poor solubility. This review article attempts to summarize several conventional methods utilized to increase the solubility of poorly soluble drugs. These methods include the principles of physical and chemical approaches such as particle size reduction, solid dispersion, supercritical fluid technology, cryogenic technology, inclusion complex formation techniques, and floating granules. It includes structural modification (i.e., prodrug, salt formation, co-crystallization, use of co-solvents, hydrotrophy, polymorphs, amorphous solid dispersions, and pH variation). Various nanotechnological approaches such as liposomes, nanoparticles, dendrimers, micelles, metal organic frameworks, nanogels, nanoemulsions, nanosuspension, carbon nanotubes, and so forth have also been widely investigated for solubility enhancement. All these approaches have brought forward the enhancement of the bioavailability of orally administered drugs by improving the solubility of poorly water-soluble drugs. However, the solubility issues have not been completely resolved, owing to several challenges associated with current approaches, such as reproducibility in large scale production. Considering that there is no universal approach for solving solubility issues, more research is needed to simplify the existing technologies, which could increase the number of commercially available products employing these techniques.

17 June 2024 in Drug Delivery and Translational Research
Verified
Journal Article
Closed access
PDF file
ABAnjali Bisht
Anjali Bisht
DADubey Avinash
Dubey Avinash
KSKantrol Kumar Sahu
Kantrol Kumar Sahu
PPPreeti Patel
Preeti Patel
GGGhanshyam Das Gupta
Ghanshyam Das Gupta
BKBalak Das Kurmi
Balak Das Kurmi

19 June 2010 in Expert Opinion on Drug Delivery
Verified
Journal Article
Closed access
BKBalak Das Kurmi
Balak Das Kurmi
JKJitendra Kayat
Jitendra Kayat
VGVirendra Gajbhiye
Virendra Gajbhiye
RTRakesh K Tekade
Rakesh K Tekade
NJNarendra K Jain
Narendra K Jain
Importance of the field: Drug delivery to lungs appears to be an attractive proposition on account of the large surface area of the alveolar region; it provides tremendous opportunities to improve drug therapies both systemically and locally using new drug delivery systems. Administration of drugs directly to the lungs is the most appropriate route in the treatment of asthma and other pulmonary diseases such as tuberculosis, chronic obstructive pulmonary disease and lung cancer.Areas covered in this review: This review focuses on the utilization of nano- and microcarriers such as microspheres, nanoparticles, liposomes, niosomes and dendrimers for targeted delivery of bioactive molecules to lungs.What the reader will gain: This review sheds light on the current status of nano- and microcarrier-mediated lung targeting of bioactive compounds.Take home message: The literature review shows that carriers could supplement sustained drug delivery to the lungs, extended duration of action, reduced therapeutic dose...

23 May 2017 in Current Drug Metabolism
Verified
Journal Article
Closed access
BKBalak Das Kurmi
Balak Das Kurmi
PTPawan Tekchandani
Pawan Tekchandani
RPRishi Paliwal
Rishi Paliwal
SPShivani Rai Paliwal
Shivani Rai Paliwal
Background: Transdermal drug delivery represents an extremely attractive and innovative route across the skin owing to the possibility for achieving systemic effect of drugs. The present scenario demands a special focus on developing safe medicine with minimized toxic adverse effects related to most of the pharmacologically active agents. Transdermal drug delivery would be a focal paradigm which provides patient convenience, first-pass hepatic metabolism avoidance, local targeting and reduction in toxic effect related to various categories of drugs like, analgesics, antiinflammatory, antibiotics, antiviral, anaesthetic, anticancer etc. Even this route has challenges due to highly organized structure of skin which acts as a main barrier to penetration of drug via the skin. Method: Several alternative possible strategies are available which overcome these barriers, including use of penetration enhancer, eletroporation, iontophoresis and various nanotechnologically developed nanocarrier systems. The latest one includes employing liposome, dendrimers, nanoparticles, ethosome, carbon nanotube and many more to avoid associated limitations of conventional formulations. Numerous transdermal products such as Estrasorb, Diractin, VivaGel®, Daytrana®, Aczone, Sileryst® are available in the market having a novel strategy to achieve higher penetration of drugs. This encourages formulation fraternity to develop structurally deformable and stable nanocarriers as an alternative approach for controlled and reliable drug delivery across the skin barrier. Discussion: In this review, we will discuss nanocarriers mediated approaches that come-up with the solutions to the different challenges towards transdermal drug delivery, its clinical importance and latest insight to research in it. Conclusion: The reports presented in this review confirm the wide application of nanocarriers for transdermal delivery of drug/gene.

1 March 2024 in Stem Cell Reviews and Reports
Verified
Journal Article
Closed access
PDF file
AVAbhinav Vashishat
Abhinav Vashishat
PPPreeti Patel
Preeti Patel
GGGhanshyam Das Gupta
Ghanshyam Das Gupta
BKBalak Das Kurmi
Balak Das Kurmi